Design of a Golden Gate Cloning Plasmid for the Generation of a Chimeric Virus-Like Particle-Based Subunit Vaccine Against Porcine Circovirus Type 2
Authors:
- Ana del Socorro Hernández-AviñaAHAna del Socorro Hernández-Aviña
- Xitlalli D. Hernández-MancillasXHXitlalli D. Hernández-Mancillas
- Jorge Alberto Salazar-GonzálezJSJorge Alberto Salazar-González
- Lorena Zapata-CuellarLZLorena Zapata-Cuellar
- Rosa María Camacho-RuizRosa María Camacho-Ruiz
- Mauricio Comas-GarcíaMauricio Comas-García
- Rosa Elena Sarmiento-SilvaRSRosa Elena Sarmiento-Silva
- Melchor Arellano-PlazaMelchor Arellano-Plaza
- Mario Alberto Flores-ValdezMFMario Alberto Flores-Valdez
- Abel Gutiérrez-OrtegaAbel Gutiérrez-Ortega
- 30 November 2024
- journal article
- research article
- Published by Springer Nature in Molecular Biotechnology
- Vol. 67 (11) , 4329-4341
Abstract
Porcine circovirus type 2 (PCV2) is a pervasive pathogen in the swine industry, leading to a spectrum of disorders known as porcine circovirus associated diseases (PCVAD). The PCV2 Cap protein contains critical antigenic epitopes and is the primary target for vaccine development. Current vaccines include inactivated viral particles and virus-like particles (VLPs), with experimental vaccines exploring various innovative approaches. This study introduces a novel Golden Gate assembly-based, Escherichia coli expression destination plasmid, pPRSVCP-E18, designed for the in-frame insertion of short peptide-coding DNA sequences into a highly antigenic site of Papaya ringspot virus (PRSV) coat protein (CP). We successfully cloned four PCV2 Cap peptides into this plasmid, expressed the chimeric CP proteins in E. coli under flask and bioreactor conditions, and assembled them into VLPs. These VLPs, when adjuvated and administered to BALB/c mice, elicited a specific IgG response against the PCV2 Cap peptides. Our findings demonstrate the plasmid’s high efficiency for Golden Gate cloning and its potential in developing subunit vaccines against PCV2, contributing to the sustainable control of PCVAD in the swine industry.Keywords
Funding Information
- Consejo Estatal de Ciencia y Tecnología de Jalisco (9261-2021)
- Sanfer Salud Animal (9261-2021)
This publication has 45 references indexed in Scilit:
- Novel constructs and 1-step chromatography protocols for the production of Porcine Circovirus 2d (PCV2d) and Circovirus 3 (PCV3) subunit vaccine candidatesFood and Bioproducts Processing, 2022
- Porcine circovirus type 2 protective epitope densely carried by chimeric papaya ringspot virus–like particles expressed in Escherichia coli as a cost‐effective vaccine manufacture alternativeBiotechnology and Applied Biochemistry, 2016
- Efficient expression and purification of porcine circovirus type 2 virus-like particles in Escherichia coliJournal of Biotechnology, 2016
- High-throughput process development of an alternative platform for the production of virus-like particles in Escherichia coliJournal of Biotechnology, 2016
- Current understanding of genomic DNA of porcine circovirus type 2Virus Genes, 2014
- The preparation of porcine circovirus type 2 (PCV2) virus-like particles using a recombinant pseudorabies virus and its application to vaccine developmentJournal of Biotechnology, 2014
- Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like particle vaccine developmentApplied Microbiology and Biotechnology, 2012
- Potato Virus Y-Like Particles as a New Carrier for the Presentation of Foreign Protein StretchesMolecular Biotechnology, 2011
- Microbial production of virus-like particle vaccine protein at gram-per-litre levelsJournal of Biotechnology, 2010
- Solubilization of active green fluorescent protein from insoluble particles by guanidine and arginineBiochemical and Biophysical Research Communications, 2003